Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Seikagaku to Cease Development of Rheumatoid Arthritis Treatment Licensed from Can-Fite
August 31, 2015
- Takeda Inks Deal with Nanotherapeutics to Expand Vaccine Technology Rights
August 28, 2015
- MTPC Chief Hints at No Major Merger, Plans Departure from Go-It-Alone Policy
August 28, 2015
- Jardiance Reduces Cardiovascular Risks: BI, Lilly
August 28, 2015
- Ono Files for Multiple Myeloma Treatment Carfilzomib in Japan
August 27, 2015
- Lixiana Recommended by UK’s NICE as Venous Thromboembolism Treatment Under National Health Service: Daiichi Sankyo
August 27, 2015
- Tresiba Approved for Pediatric Use: Novo Nordisk
August 27, 2015
- ASKA to Launch Authorized Generics of Takeda’s Unisia
August 26, 2015
- Artist Approved for Tachycardiac Atrial Fibrillation: Daiichi Sankyo
August 26, 2015
- Cravit Approved for Pulmonary Tuberculosis: Daiichi Sankyo
August 26, 2015
- Ono, Novartis Gain Approval of One-Step Titration Regimen for AD Drug Rivastigmine
August 26, 2015
- Chugai Files CellCept for Lupus Nephritis Based on Information in Public Domain
August 26, 2015
- Novo Nordisk to Roll Out NovoThirteen on Aug. 27
August 25, 2015
- Japan to Participate in Global PIII Study of Forxiga for Type 1 Diabetes: AZ
August 25, 2015
- ASCO Immunotherapy Roundup - 8: 5 Immune Checkpoint Inhibitors Projected to Rake in 2 Trillion Yen in 2020
August 25, 2015
- Eli Lilly Files for Psoriasis Treatment Ixekizumab in Japan
August 24, 2015
- Janssen, National Center of Neurology and Psychiatry to Jointly Develop Biomarkers for AD Drug Reminyl
August 24, 2015
- EMA Accepts Application for Once-Weekly Oral Proteasome Inhibitor Ixazomib: Takeda
August 24, 2015
- Lilly Challenges Invalidation Ruling on Evista Usage Patent
August 21, 2015
- Astellas to Adopt One-Rep-for-One-Institution Regime in October
August 21, 2015
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…